When does the label say to call your doctor?
From the Patient Information that comes with Lantus:
- Signs of a severe allergic reaction, such as a rash over your whole body, trouble breathing, a fast heartbeat or sweating: get medical help right away.
- Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue or throat, sweating, extreme drowsiness, dizziness or confusion: get emergency medical help.
- New or worse symptoms of heart failure while taking a TZD with Lantus, such as shortness of breath, swelling of the ankles or feet, or sudden weight gain: tell your healthcare provider.
- Lantus that looks cloudy or slightly colored: return it to your pharmacy for a replacement.
What are the most common Lantus side effects?
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Lantus.
| Adverse reaction | LANTUS, % (n=1,257) | NPH, % (n=1,070) |
|---|---|---|
| Upper respiratory tract infection | 22.4 | 23.1 |
| Infection | 9.4 | 10.3 |
| Accidental injury | 5.7 | 6.4 |
| Headache | 5.5 | 4.7 |
Studies A to D, compared with NPH insulin rather than placebo. Infection means body system not specified.
| Adverse reaction | LANTUS, % (n=849) | NPH, % (n=714) |
|---|---|---|
| Upper respiratory tract infection | 11.4 | 13.3 |
| Infection | 10.4 | 11.6 |
| Retinal vascular disorder | 5.8 | 7.4 |
Studies E to G, compared with NPH insulin. Infection means body system not specified.
| Adverse reaction | LANTUS, % (n=514) | NPH, % (n=503) |
|---|---|---|
| Upper respiratory tract infection | 29.0 | 33.6 |
| Edema peripheral | 20.0 | 22.7 |
| Hypertension | 19.6 | 18.9 |
| Influenza | 18.7 | 19.5 |
| Sinusitis | 18.5 | 17.9 |
| Cataract | 18.1 | 15.9 |
| Cough | 12.1 | 7.4 |
A 5-year study against NPH insulin; rates are over the full 5 years. The full table also lists bronchitis, joint pain, limb pain, back pain, urinary tract infection, diarrhea, depression and headache at 10.3% to 15.2% on Lantus.
| Study | LANTUS | NPH |
|---|---|---|
| Study A, adults, 28 weeks, with regular insulin (N=292 vs 293) | 10.6 | 15.0 |
| Study B, adults, 28 weeks, with regular insulin (N=264 vs 270) | 8.7 | 10.4 |
| Study C, adults, 16 weeks, with insulin lispro (N=310 vs 309) | 6.5 | 5.2 |
| Study D, pediatrics, 26 weeks, with regular insulin (N=174 vs 175) | 23.0 | 28.6 |
Severe symptomatic hypoglycemia means needing another person's help, with blood glucose below 50 mg/dL or prompt recovery after carbohydrate, glucose or glucagon. Values are percent of patients.
| Study | LANTUS | NPH |
|---|---|---|
| Study E, adults, 52 weeks, with oral agents (N=289 vs 281) | 1.7 | 1.1 |
| Study F, adults, 28 weeks, with regular insulin (N=259 vs 259) | 0.4 | 2.3 |
| Study G, adults, 5 years, with regular insulin (N=513 vs 504) | 7.8 | 11.9 |
Values are percent of patients. The 5-year study used a glucose cut-off of 56 mg/dL or less.
Other numbers in the Adverse Reactions section
- Section 6.1Table 7, ORIGIN study (median 6.2 years): severe symptomatic hypoglycemia in 5.6% on Lantus (N=6231) vs 1.8% on standard care (N=6273).
- Section 6.1Table 4, children with type 1 diabetes over 28 weeks (Lantus vs NPH): infection 13.8% vs 17.7%, upper respiratory infection 13.8% vs 16.0%, pharyngitis 7.5% vs 8.6%, rhinitis 5.2% vs 5.1%.
Show 3 more findingsShow fewer
- Section 6.1Injection site pain was reported in 2.7% of adults on Lantus vs 0.7% on NPH insulin; it did not lead anyone to stop treatment.
- Section 6.1Rapid improvement in blood sugar has been linked to a temporary, reversible vision refraction change, worsening of diabetic retinopathy and acute painful nerve pain. Weight gain and swelling from sodium retention can also occur.
- Section 6.3Reported after approval: mix-ups where other insulins were given instead of Lantus, and localized cutaneous amyloidosis (lumps under the skin) at injection sites.
What serious risks does the Lantus label warn about?
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
- Section 4Who should not use it. Lantus is not used during an episode of low blood sugar, or by people allergic to insulin glargine or its ingredients.
- Section 5.1Never share pens, needles or syringes. A Lantus SoloStar pen is never shared, even if the needle is changed, and vial needles and syringes are never reused or shared, because of the risk of passing on blood-borne infections.
- Section 5.2Changes in insulin regimen. Changing insulin strength, maker, type, injection site or method can cause high or low blood sugar, so changes are made under close supervision with more glucose checks. Injecting into lumpy or thickened skin can raise blood sugar, and switching to normal skin can lower it suddenly.
- Section 5.3Low blood sugar. Hypoglycemia is the most common reaction to insulin, and severe episodes can cause seizures or death. Lantus's long action may delay recovery from a low. Awareness of lows may be reduced with long diabetes, nerve damage, beta-blockers or repeated lows.
Show 4 more risksShow fewer
- Section 5.4Medication mix-ups. Mix-ups between insulin products have been reported, so the insulin label is checked before each injection.
- Section 5.5Serious allergic reactions. Severe, life-threatening whole-body allergy, including anaphylaxis, can occur; Lantus is stopped if it does.
- Section 5.6Low potassium. All insulins shift potassium into cells and can cause low potassium, which untreated can cause breathing paralysis, heart rhythm problems and death.
- Section 5.7Heart failure with TZDs. Thiazolidinediones (such as pioglitazone) with insulin can cause fluid retention that may lead to or worsen heart failure.
Does Lantus have a boxed warning?
No. The current Lantus label has no boxed warning.
How do I keep track of side effects in Dose Track?
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own.
Read moreRead less
The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
Frequently asked questions
What is the most common side effect of Lantus?
Low blood sugar (hypoglycemia), as with all insulins (section 5.3). Leaving that aside, upper respiratory infection was most common: 22.4% in adults with type 1 and 11.4% with type 2 diabetes, similar to NPH insulin (section 6.1, Tables 1 and 2).
How often did severe low blood sugar happen on Lantus?
In adult type 1 studies, 6.5% to 10.6% of patients vs 5.2% to 15.0% on NPH; in children, 23.0% vs 28.6%. In type 2 studies, 0.4% to 7.8% vs 1.1% to 11.9% (section 6.1, Tables 5 and 6).
Does Lantus cause injection site pain?
Sometimes. Injection site pain was reported in 2.7% of adults on Lantus vs 0.7% on NPH insulin, and it did not lead anyone to stop treatment (section 6.1).
Does Lantus have a boxed warning?
No. The Lantus label has no boxed warning. Its warnings cover sharing pens, regimen changes, low blood sugar, mix-ups, allergic reactions, low potassium and heart failure with TZDs (section 5).
Can Lantus cause weight gain?
Yes. The label says weight gain has occurred with insulin including Lantus, attributed to insulin's anabolic effects and less sugar lost in the urine (section 6.1).
Related pages
- Lantus dosing schedule from the same label
- Missed a dose of Lantus? What the label says
- Free reconstitution calculator
Show similar medicinesShow fewer
Side effects for similar medicines
- Actoplus Metpioglitazone and metformin hydrochloride
- Actospioglitazone
- Admeloginsulin lispro injection 100 units/mL
- Afrezzainsulin human inhalation powder
- Apidrainsulin glulisine injection 100 units/mL
- Baqsimiglucagon nasal powder 3 mg
- Basaglarinsulin glargine 100 units/mL
- Cyclosetbromocriptine mesylate
See also
- Insulin Glargine: pens, label dosing and how long it acts
- Basaglar dosing schedule
- I missed my Toujeo dose. What should I do?
- Semglee side effects
- Toujeo side effects
Track it in Dose Track: GLP-1 tracker, TRT tracker or peptide tracker.
Sources
- LANTUS (insulin glargine) injection, for subcutaneous use, prescribing information, Patient Information and Instructions for Use. Sanofi-Aventis U.S.. DailyMed, version published July 2, 2025. DailyMed setid d5e07a0c-7e14-4756-9152-9fea485d654a
What Lantus is approved forHide
Lantus is a long-acting human insulin analog approved to improve blood sugar control in adults and children with diabetes (section 1). It is not recommended for treating diabetic ketoacidosis.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.
All side-effect pages · Dosing schedules · Missed dose guides · Compound guides